MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.semradonc.2025.04.011

Медицинская библиотека · Seminars in radiation oncology · 2025

Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach.

von Amsberg Gunhild, Kaune Moritz, Coym Anja, Strewinsky Nadja, Falkenbach Fabian, Hohenhorst Jan Lukas, Tilki Derya, Dyshlovoy Sergey

СтатьяОбзорПеревод в очереди

Аннотация

Oligometastatic prostate cancer (OMPC) represents an intermediate stage between localized and extensive metastatic disease, characterized by a limited number of metastatic lesions. While metastasis-directed therapy (MDT) has gained traction for its potential to delay systemic therapy, systemic therapy itself is falling behind. In our view, this is not appropriate at the current stage. In the context of this controversy, we highlight the points that emphasize the role of systemic therapy in OMPC and point out weaknesses of data available on local treatment concepts. The lack of a standardized OMPC definition complicates the comparison of results across studies. Imaging inconsistencies, ranging from conventional techniques to advanced PSMA-PET/CT, further challenge accurate classification. Additionally, the biological basis of OMPC remains unclear, with no definitive biomarkers distinguishing it from polymetastatic disease. While MDT has demonstrated improved progression-free survival in small trials, its impact on overall survival remains inconclusive. Conversely, systemic therapy with androgen receptor pathway inhibitors (ARPIs) has shown a significant survival advantage in phase 3 trials. Subgroup analyses from large trials indicate a benefit of systemic therapy, particularly in low-volume disease. Combination strategies incorporating MDT and systemic therapy may optimize outcomes. Further research is needed to refine patient selection, integrate molecular biomarkers, and establish the optimal treatment paradigm. Until robust evidence emerges, systemic therapy remains the standard of care for OMPC.

Для цитирования: von Amsberg Gunhild, Kaune Moritz, Coym Anja, Strewinsky Nadja, Falkenbach Fabian, Hohenhorst Jan Lukas, Tilki Derya, Dyshlovoy Sergey. Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach.. Seminars in radiation oncology. 2025. DOI: 10.1016/j.semradonc.2025.04.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.